BONESUPPORT announced publication of mid- to long-term data confirming the sustained clinical effectiveness of CERAMENT G, an injectable drug-eluting bioceramic bone graft substitute, in a single-stage protocol to manage chronic osteomyelitis.
The study followed 100 patients. Results at a mean follow-up of 6.05 years were reported:
94% of patients remained infection-free
3% fracture rate and no further pathologic fractures beyond the first year after surgery
“These results over a long follow-up period confirm that our protocol using CERAMENT G remains highly effective over several years. There are hardly any prospective studies on bone graft substitutes with a follow-up over two years. Additionally, we were able to achieve these results in single-stage operation due to CERAMENT G’s unique properties of eluting high concentrations of local antibiotics and providing bone remodeling. Reducing the number of surgical procedures is more patient-friendly and allows for a cost-effective strategy to tackle chronic osteomyelitis,” said Professor Martin McNally, lead author and lead consultant in limb reconstruction surgery at Oxford University Hospital.
CERAMENT G is implanted to promote bone healing in bone voids or defects and simultaneously to protect it from infection. More than 70,000 patients have been treated thus far using the CERAMENT bone healing technology.
BONESUPPORT announced publication of mid- to long-term data confirming the sustained clinical effectiveness of CERAMENT G, an injectable drug-eluting bioceramic bone graft substitute, in a single-stage protocol to manage chronic osteomyelitis.
The study followed 100 patients. Results at a mean follow-up of 6.05 years were reported:
94% of...
BONESUPPORT announced publication of mid- to long-term data confirming the sustained clinical effectiveness of CERAMENT G, an injectable drug-eluting bioceramic bone graft substitute, in a single-stage protocol to manage chronic osteomyelitis.
The study followed 100 patients. Results at a mean follow-up of 6.05 years were reported:
94% of patients remained infection-free
3% fracture rate and no further pathologic fractures beyond the first year after surgery
“These results over a long follow-up period confirm that our protocol using CERAMENT G remains highly effective over several years. There are hardly any prospective studies on bone graft substitutes with a follow-up over two years. Additionally, we were able to achieve these results in single-stage operation due to CERAMENT G’s unique properties of eluting high concentrations of local antibiotics and providing bone remodeling. Reducing the number of surgical procedures is more patient-friendly and allows for a cost-effective strategy to tackle chronic osteomyelitis,” said Professor Martin McNally, lead author and lead consultant in limb reconstruction surgery at Oxford University Hospital.
CERAMENT G is implanted to promote bone healing in bone voids or defects and simultaneously to protect it from infection. More than 70,000 patients have been treated thus far using the CERAMENT bone healing technology.
Copy to clipboard 
